New drug JR8603 enters first human trial for Hard-to-Treat cancers
Disease control
Recruiting now
This early-stage trial tests the safety and effectiveness of a new drug called JR8603 in people with advanced solid tumors, including stomach and colorectal cancers, who have not responded to standard treatments. Participants receive JR8603 by IV infusion three times per month. T…
Phase: PHASE1 • Sponsor: JiaRay Group • Aim: Disease control
Last updated Jun 26, 2026 15:14 UTC